May 24, 2023Open Access
Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Upadacitinib induction and maintenance treatment was superior to placebo in patients with moderate-to-severe Crohn's disease. (Funded by AbbVie; U-EXCEL, U-EXCEED, and U-ENDURE ClinicalTrials.gov numbers, NCT03345849, NCT03345836, and NCT03345823.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Edward V. Loftus
Ulsan College
Julián Panés
Hospital Clínic de Barcelona
A
Ana P. Lacerda
AbbVie (United States)
Journals
New England Journal of Medicine
Actions
Institutions
Inserm
Icahn School of Medicine at Mount Sinai
University of Calgary
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...